Skip to main content

Table 1 Baseline demographics and clinical characteristics

From: Increased IL-17RA and IL-17RC in End-Stage COPD and the Contribution to Mast Cell Secretion of FGF-2 and VEGF

 

Never smokers

Smokers w/o COPD

COPD GOLD I

COPD GOLD II-III

COPD GOLD IV

p ANOVA

Subjects (n)

7

6

6

13

10

 

Gender (female/male)

5/2

4/2

3/3

2/11

6/4

 

Age (years)

63 ± 4.8

57 ± 3.3

67 ± 2.9

68 ± 1.9

61 ± 1.4

ns

Height (m)

1.64 ± 0.1

1.71 ± 0.1

1.74 ± 0.1

1.73 ± 0.1

1.69 ± 0.1

ns

Weight (kg)

65 ± 4.6

69 ± 4.6

69 ± 5.7

73 ± 3.1

65 ± 1.7

ns

Body mass index

24 ± 1.3

24 ± 1.0

23 ± 1.2

24 ± 1.1

23 ± 1.0

ns

Pack years

N/A

43 ± 8.2

40 ± 7.6

48 ± 3.3

41 ± 3.9

ns

Smoker/ex-smoker

N/A

4/2

3/3

5/8

0/10

 

FEV1/FVC

86 ± 5.7

79 ± 2.0

67 ± 0.9

55 ± 2.8

32 ± 2.0

<0.001

%FEV1

110 ± 6.2

98 ± 6.0

87 ± 2.3

64 ± 3.1

23 ± 1.4

<0.001

Corticosteroids (yes/no/unknown)

0/7/0

0/6/0

0/6/0

2/11/0

9/0/1

 

Bronchodialator (yes/no/unknown)

0/7/0

0/6/0

3/3/0

3/10/0

9/0/1

 
  1. Values are mean ± standard error of mean
  2. COPD chronic obstructive pulmonary disease, FEV 1 forced expiratory volume in 1 s, (F)VC (forced) vital capacity, GOLD Global Initiative for Chronic Obstructive Lung Disease